Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Further payments remain milestone-dependent, with Wave eligible for tiered royalties on net sales for each collaboration program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Wave Life Sciences (WVE) announced GSK’s selection of a hepatology candidate for its development pipeline, triggering a $12 million milestone payment.
The candidate was developed using Wave’s proprietary SpiNA design GalNAc-siRNA, an RNA-based approach, under the companies’ research collaboration. Wave will receive the selection payment and is eligible for up to $330–$375 million in development, launch and commercial milestones for each collaboration program, plus tiered royalties on net sales. Wave is also advancing three additional collaboration programs toward potential candidate selection.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Wave is eligible for up to $330–$375 million per program in milestones, plus tiered royalties on net sales. 52% of market cap
- Moderate pointGSK’s hepatology candidate selection advances a Wave-developed program toward GSK’s development pipeline.
- Minor pointCandidate selection triggers a $12 million milestone payment to Wave.
- Minor point. Forward-looking: it has not happened yet and may not happen.Three additional collaboration programs are advancing toward potential candidate selection.
Negative
- None.
Details
Market move: WVE +4.40% vs previous close. siRNA program partnership
On Sep 30, the day this news came out, the latest delayed price for WVE is 4.40% above the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $3.80. Relative volume is very high at 4.7x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Milestone payment
- $12 million
- Payable to Wave for candidate selection
- Potential milestones per program
- Up to $330 - $375 million
- Development, launch, and commercial milestones for each collaboration program
- Additional programs
- 3 programs
- Collaboration programs advancing toward potential candidate selection
Key Terms
sirna medical
galnac-sirna medical
ago2 medical
tiered royalties financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. This program was developed using Wave’s proprietary SpiNA design GalNAc-siRNA.
“The advancement of this development candidate by GSK reflects the recognition of Wave’s differentiated technology, including our best-in-class SpiNA design siRNA,” said Paul Bolno, MD, MBA. “Our SpiNA siRNA compounds demonstrate superior pharmacology, including improved potency, durability and Ago2 loading versus comparator formats. Our collaboration with GSK continues to leverage the versatility of our PRISM™ platform coupled with human genetic insights to advance novel oligonucleotide therapeutics. With this new hepatic program now transitioning to candidate, our collaboration momentum continues as we have three additional programs rapidly advancing towards candidate selection, all leveraging our proprietary PRISM chemistry.”
Wave will receive a
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations for programs we develop using our proprietary SpiNA design GalNAc-siRNA and their best-in-class potential; our potential to earn substantial additional milestone payments and tiered royalties under our GSK collaboration; and our belief supported by data that our SpiNA siRNA compounds demonstrate superior therapeutic properties than comparator formats. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much will Wave Life Sciences receive for GSK’s candidate selection?
Wave will receive a $12 million milestone payment for GSK’s selection of the hepatology candidate. The program was developed under the companies’ research collaboration using Wave’s proprietary SpiNA design GalNAc-siRNA.
What additional payments is Wave Life Sciences eligible for under the GSK collaboration?
Wave is eligible for up to $330–$375 million in development, launch and commercial milestones for each collaboration program, plus tiered royalties on net sales. These are potential additional payments, not amounts already received.